Back to search

Peptide record

TPDB40710

Pep-1-Phor21 Anticancer standard
30 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40710
Pep-1-Phor21
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 30-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
CGEMGWVRCKFAKFAKKFAKFAKKFAKFAK
Physicochemical Analysis
C168H257N43O33S3
NDQHILPSTY
K
3503.34
10.81
10
1
15
+9
1.47
-0.203
29.67
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
5625
160.56
2
Residue Composition
number
6
A
1
R
0
N
0
D
2
C
1
E
0
Q
2
G
0
H
0
I
0
L
9
K
1
M
6
F
0
P
0
S
0
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 6 R: 1 N: 0 D: 0 C: 2 E: 1 Q: 0 G: 2 H: 0 I: 0 L: 0 K: 9 M: 1 F: 6 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 1
Chemical Descriptors
30
C168H257N43O33S3
3503.34
10.81
+9
1.47
-0.203
Free
L
Linear
Free
Anticancer
Hybrid peptide PEP1 and Phor 21
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 55.13 ± 13.56 µM
Anticancer
55.13

Target

Liver Cancer
LNCaP
Liver

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 2.57 ± 2.02 µM
Anticancer
2.57

Target

Prostrate Cancer
DU-145
Prostate

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023
Evidence 3 Activity

Activity

IC50
IC50 ≤ 0.6 µM
Anticancer
0.6 µM

Target

Prostrate Cancer
PC-3
Prostate

Assay & Model

AlamarBlue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023